Adine Regan, MD
Urology · Farmington, CTNPI 1538250055
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $448 of the $539 with a category attached, or 83.1%. It is spread thinly across 14 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $152 and has fallen 66.1% since, to $51 in 2024. That places this record below the midpoint for urology clinicians in CT, where the typical reported total is $1,704.
Across 23 payments — averaging $23.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$119
- Urovant Sciences Inc$80
- Dentsply IH Inc.$78
- Dentsply IH AB$46
- AbbVie$39
- Pfizer$28
- plus $149 from 8 others
Across 11 payments — averaging $3239.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$36K
What the payments were for
- Food & beverage$44883%
- Education$9117%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 3 | $119 |
| Urovant Sciences Inc | 4 | $80 |
| Dentsply IH Inc. | 3 | $78 |
| Dentsply IH AB | 1 | $46 |
| AbbVie(2 entities) | 2 | $39 |
| Pfizer | 2 | $28 |
| Medtronic | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Duchesnay USA Incorporated | 1 | $22 |
| Therapeuticsmd, Inc. | 1 | $20 |
| Hollister Incorporated | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $14 |
| Coloplast | 1 | $14 |
How this compares
$539 in reported general payments places this provider in the 30th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 268 | $260,689 |
| GemtesaVibegron | 179 | $206,401 |
| Mirabegron ErMirabegron | 39 | $29,093 |
| Methenamine Hippurate | 362 | $22,328 |
| YuvafemEstradiol | 87 | $12,173 |
| Estradiol | 145 | $12,049 |
| Trospium Chloride ErTrospium Chloride | 45 | $11,290 |
| Solifenacin Succinate | 200 | $10,537 |
| EstringEstradiol | 17 | $8,891 |
| PremarinEstrogens, Conjugated | 15 | $6,610 |
| Oxybutynin Chloride ErOxybutynin Chloride | 219 | $5,263 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 59 | $4,965 |
| ToviazFesoterodine Fumarate | 11 | $4,507 |
| Trospium Chloride | 59 | $4,466 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 229 | $2,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $119 | $260,689268 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $22 | $206,401179 claims |
| PfizerEstring, Premarin, Toviaz | $28 | $20,00943 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 156 urology providers in Connecticut.
Other urology in Farmington
- Ryan DorinFarmington$17K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Joshua SteinNew Britain$30K
- Steven ShichmanHartford$28K
- Christine LiawBridgeport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.